PCMA urges passage of biosimilars legislation

WASHINGTON The release of a report by the Government Accountability Office has prompted a pharmacy benefit manager association to urge the passage of biosimilars legislation.

The Pharmaceutical Care Management Association released a statement Tuesday following the GAO’s report on the Federal Employees Health Benefits Program and enrollee cost sharing for selected specialty prescription drugs.

“The high prices of biotech drugs in the new GAO report underscore the importance of creating much-needed competition to lower costs and increase access for these life-saving products,” the statement read.

As of Tuesday, no additional action had been taken on two competing bills going through the House of Representatives that would legalize biosimilars, albeit with different exclusivity periods, or on a companion bill to one of them in the Senate.